SABCS 2024
Dec 10 - 13, 2024 | San Antonio, TX
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Abemaciclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Preliminary Phase 1b ResultsJ Hilton et al.
Poster
Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors and EverolimusW Tan et al.
Poster
Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor Degrader, Plus Palbociclib in CDK4/6 Inhibitor–Resistant Wild-Type and Estrogen Receptor Y537S–Mutant Patient-Derived Xenograft ModelsJ Teh et al.